CTNNB1 and adrenal gland neoplasm: Researchers have found that the expression level of ISM1 was significantly upregulated in both CTNNB1 mutated adrenal tumors and CTNNB1 mutated adrenal lesions, suggesting that ISM1 may be a potential therapeutic target for CTNNB1 mutation-related adrenal disease (53).